source
- AstraZeneca reports promising triplet therapy results in liver cancer subgroupAstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…
- Priority review voucher prices have doubled over three years, likely to remain highRecent reporting highlights that the price of FDA priority review vouchers has roughly doubled from three years ago. The vouchers provide a shortcut that can shave about four months off the agency…